FIGURE 5.

Intracellular delivery of AT₂R activator C21 decreased the APs of mESC-CMs. (A) Dual current patch clamp of APs of mESC-CMs without intracellular drug delivery (i.e., before membrane breakage by the “drug electrode”). Upper panel represents recording in the “drug electrode” while the lower panel represents recording in the “recording electrode.” (B) Dual current patch clamp of APs of mESC-CMs with intracellular delivery of C21 (i.e., after membrane breakage by the “drug electrode”). Upper panel represents recording in the “drug electrode” while the lower panel represents recording in the “recording electrode.” (C) Traces labeled as pink in (A) (represents APs before intracellular C21 delivery) and as blue in (B) (represents APs after intracellular intracellular C21 delivery) are overlaid for comparison. (D–G) Summarized data on the (D) AP rate, (E) DD slope, (F) APD50, and (G) MDP of APs upon treatment with intracellular C21. Values are mean ± SEM of 6–10 independent experiments. *p < 0.05 vs. control group.